By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.
Histologically proven first diagnosis of cHL
Stage I-II without risk factors
Large mediastinal mass
Extranodal involvement
Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,
Prior cHL-directed treatment
Prior chemotherapy, RT or allogeneic stem cell/solid organ transplant
Prior or concurrent disease precluding protocol treatment (for details see section 4.2)